Molotinib momelotinib 200mg

Product Information

• Catalog product: TLPH Molotinib momelotinib 200mg
• Listed manufacturer: TLPH Pharma, Laos
• Active ingredient and strength: momelotinib, 200mg
• AISTIKA SKU: AM-ITEM-2

Product Summary

Molotinib identifies this TLPH momelotinib 200mg catalog item. Check the ingredient spelling as well as the brand and SKU when matching an order request. The current price and stock shown on this page apply to this listing, not to all momelotinib packs or to an entire treatment course.

Active Ingredient and Reference Data

The clinical sections use public information about momelotinib. They do not establish regulatory approval, manufacturing quality or bioequivalence for the listed TLPH item. US and European indications have different wording; the reference indication and dosage below follow the US label, while the EMA overview supports the mechanism and common-effect explanation.

Mechanism of Action

Momelotinib inhibits Janus kinase signaling and ACVR1, a protein involved in iron regulation. These actions help explain its role in myelofibrosis with anemia rather than making it a general treatment for every cause of low hemoglobin. The EMA overview describes how this can affect inflammation and iron availability.

Reference Indications

The FDA reference population is adults with anemia and intermediate- or high-risk myelofibrosis, including primary disease and disease following polycythemia vera or essential thrombocythemia. This is a specific hematology setting, not an indication for all blood disorders or uncomplicated anemia. The FDA trial snapshot explains the patient groups evaluated.

Reference Dosage and Administration

The US reference dosage is 200mg once daily, with or without food: one 200mg tablet when clinically appropriate. Severe hepatic impairment requires a lower starting dose, and toxicity may require interruption or adjustment. A physician must choose the regimen; a pharmacist should verify the actual product insert.

Important Safety Information

Infections, low platelets or neutrophils, liver injury and severe skin reactions need medical monitoring. The label also addresses cardiovascular events, thrombosis, malignancies and symptom flare after interruption. Do not stop or interrupt treatment without medical advice. Fever, unusual bleeding or a blistering rash requires prompt assessment.

Common Adverse Reactions and Monitoring

Reported common effects include low platelets, diarrhea, nausea, headache, dizziness and tiredness. Clinicians check blood counts and liver tests before and during therapy. Symptoms alone cannot replace laboratory monitoring.

Drug Interactions and Special Populations

OATP1B1/B3 inhibitors can increase exposure, while BCRP-substrate medicines such as rosuvastatin may need adjustment. A pharmacist should review the complete medicine list. Pregnancy may involve fetal risk; breastfeeding is not advised during treatment.

Storage and Purchase Notes

Use storage conditions printed on the supplied Molotinib package. Do not assume another manufacturer’s bottle, desiccant or expiry instructions apply. Ask for the pack quantity, batch, expiry and insert before relying on a catalog image to identify the supplied pack. Destination rules and delivery arrangements require separate confirmation.

Medical information basis: official public product labeling and regulatory safety information.

Disclaimer

This is educational catalog information, not a diagnosis, personalized dose or guarantee of local authorization or therapeutic equivalence. A qualified physician and pharmacist must assess suitability, monitoring and the labeling supplied with the actual product.